Infection and immunity
Conditions
Interventions
Intervention group:On top of the anti-tuberculosis treatment(HRptE/HELfx/HRE), add Rhodiola Rosea injection, 10 mL of Rhodiola Rosea injection (Tonghua Yusheng Pharmaceutical Co., Ltd., State Pharmaco
Control group :Anti-tuberculosis treatment (HRptE/HELfx/HRE)
Sponsors
Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
Eligibility
Sex/Gender
All
Age
60 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Age 60-80 years; 2) Any gender; 3) Those with a confirmed diagnosis of sensitive tuberculosis; 4) Duration of current anti-tuberculosis treatment less than 2 weeks; 5) Traditional Chinese Medicine (TCM) typology of Yin deficiency and fire type/Qi deficiency type; 6) Patient's compliance and geographical location of residence to meet the need for follow-up; 7) Signed informed consent form.
Exclusion criteria
Exclusion criteria: 1) Persons with severe cardiac, pulmonary, cerebral, renal, gastrointestinal and systemic systemic diseases; 2) Concomitant application of drugs affecting the efficacy observed in this study; 3) Those who are allergic or intolerant to the study drug 4) Those with poor compliance who cannot cooperate; 5) HIV-positive persons; 6) Other subjects who, in the opinion of the investigator, are unable to complete the study as required, or are unsuitable for follow-up participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of immune cell subsets;Cytokines;Sputum cultures;clinical symptoms; | — |
Countries
China
Contacts
Public ContactYan bo
Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
Outcome results
None listed